Plasma concentrations of natriuretic peptides (NP) contribute to risk stratification and management of patients undergoing non-cardiac surgery. However, genetically determined variability in the levels of these biomarkers has been described previously. In the perioperative setting, genetic contribution to NP plasma level variability has not yet been determined. A cohort of 427 patients presenting for non-cardiac surgery was genotyped for single-nucleotide polymorphisms (SNPs) from the NPPA/NPPB locus. Haplotype population frequencies were estimated and adjusted haplotype trait associations for brain natriuretic peptide (BNP) and amino-terminal pro natriuretic peptide (NT-proBNP) were calculated. Five SNPs were included in the analysis. Compared to the reference haplotype TATAT (rs198358, rs5068, rs632793, rs198389, rs6676300), haplotype CACGC, with an estimated frequency of 4%, showed elevated BNP and NT-proBNP plasma concentrations by 44% and 94%, respectively. Haplotype CGCGC, with an estimated frequency of 9%, lowered NT-proBNP concentrations by 28%. ASA classification status III and IV, as well as coronary artery disease, were the strongest predictors of increased NP plasma levels. Inclusion of genetic information might improve perioperative risk stratification of patients based on adjusted thresholds of NP plasma levels.
Acute Kidney Injury (AKI) is prevalent in intensive care units (ICU) and is linked with increased mortality. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines define AKI using serum creatinine and urinary output criteria. While moderate and severe AKI according the creatinine criterion correlate with increased mortality, the significance of stage 1 AKI remains debated. Retrospective cohort analysis from two tertiary care centres in Switzerland and Austria (2013-2021) to investigate the association between stage 1 AKI (KDIGO creatinine criterion) in the first seven days after ICU admission and one-year mortality in adult ICU patients. Data were extracted using standardized protocols. Baseline creatinine was determined using estimation formulas. We applied multivariable regression models adjusted for key confounders and conducted sensitivity analyses. Of 42,446 patients, 4667 (11 %) developed stage 1 AKI, 13 % (n = 5449) moderate/ severe AKI and 32,330 patients no AKI (76 %). Stage 1 AKI associates with one-year mortality (OR 1.6 [95 %CI 1.48; 1.73], p < 0.001) and increases length of stay in ICU (β 1.4 [95 %CI 1.2; 1.5], p < 0.001) and hospital (β 2.7 [95 %CI 2.1; 3.2], p < 0.001). In subgroup-analyses, we observed similar associations in patients with surgery (OR 1.66 [95 %CI 1.45;1.89], p < 0.001) and without surgery (OR 1.61 [95 %CI 1.46;1.78], p < 0.001). Stage 1 AKI is associated with 1-year mortality in adult ICU patients even in steps below 26.5 μmol/L. This highlights the prognostic significance of subclinical renal injury and underlines the need for increased efforts to diagnose AKI in its full spectrum. The analysis is limited by basing the AKI diagnosis on creatinine criterion.
Fluid accumulation is a known risk factor of adverse renal outcomes in critically ill patients. A substantial proportion of the fluid burden in intensive care unit (ICU) patients arises from maintenance fluids and fluid creep. Whether these non-resuscitation fluids affect renal outcomes remains uncertain. Retrospective cohort study of adult ICU patients admitted to a tertiary care center in Switzerland between January 2014 and December 2017. The primary objective was the association of fluid creep/maintenance fluid intake with major adverse kidney events within 30 days (MAKE30). Secondary endpoints included the individual components of MAKE30: mortality, renal replacement therapy (RRT), and persistent renal dysfunction. Associations were analysed using multivariable logistic regression adjusted for typical confounders. 12,716 patients were included, of whom 1812 (14%) experienced MAKE30. The median total volume of fluid creep/maintenance fluids until ICU discharge was 716 mL (Interquartile range [IQR] 329; 2128), corresponding to a median daily intake of 8 mL/kg (IQR 4; 15). Each additional milliliter of fluid creep/maintenance fluids per kilogram body weight per day was associated with MAKE30 (adjusted odds ratio [aOR] 1.004, 95% confidence interval [CI] 1.001-1.008; p = 0.016) and all its components, including 30-day mortality, RRT, and persistent renal dysfunction. In a large mixed ICU cohort, higher exposure to fluid creep/ maintenance fluids was consistently associated with MAKE30 and its components. Fluid creep should be recognized as a modifiable component of fluid therapy. Future studies are needed to determine how reducing the dose of hidden fluids affects clinical outcomes.